"The FDA issued a rare disease priory review voucher (PRV) accompanying the approval for Casgevy but not for Lyfgenia. Companies can use these vouchers to expedite FDA’s review of other drugs.
Analysts at Cantor suspected that because bluebird already got a PRV on Zynteglo, which is a twin therapy to Lyfgenia, the FDA may have viewed the request for a new PRV as double-dipping."
Market Data 
Markets 
AI
